Cancer · 2007 · 247 citations · 30 references
MedicineOncologyPharmacologyCancer PharmacologyGastrointestinal OncologyMolecular OncologyHepatobiliary CancerHepatocellular CarcinomaHepatocellular Carcinoma PharmacotherapyLiver CancerMalignant NeoplasmsTargeted TherapyCetuximab TherapyChimeric Monoclonal AntibodiesEgfr InhibitionEpidermal Growth Factor Receptor InhibitionHepatocellular Carcinoma MetastasisHepatocellular Carcinoma TreatmentLiver Tumor TherapyMolecularly Targeted Agents
BACKGROUND: Epidermal growth factor receptor (EGFR) and ligand expression is frequently seen in hepatocellular carcinoma (HCC). A phase 2 study was performed with cetuximab, a chimeric monoclonal antibody that binds specifically to EGFR, in patients with advanced HCC. METHODS: Eligibility criteria included unresectable or metastatic measurable HCC, an Eastern Cooperative Oncology Group performance status <or=2, Cancer of the Liver Italian Program (CLIP) score <or=3, and adequate organ functions. The initial dose of cetuximab was 400 mg/m(2) given intravenously followed by weekly intravenous infusions at 250 mg/m(2). Each cycle was defined as 6 consecutive weekly treatments. EGFR expression was assayed by immunohistochemistry and trough serum concentrations of cetuximab were determined during the first cycle. RESULTS: Thirty patients were enrolled and assessable for efficacy and toxicity. No responses were seen. Five patients had stable disease (median time, 4.2 months; range, 2.8-4.2 months). The median overall survival was 9.6 months (95% confidence interval [CI], 4.3-12.1 months) and the median progression-free survival (PFS) was 1.4 months (95% CI, 1.2-2.6 months). The treatment was generally well tolerated. No treatment-related grade 4-5 toxicities occurred. Grade 3 (according to the National Cancer Institute's Common Terminology Criteria for Adverse Events [version 3.0]) aspartate aminotransferase, hypomagnesemia, and fever without neutropenia were noted in 1 patient (3.3%) each. On Week 6 of Cycle 1, arithmetic mean serum cetuximab concentrations for patients with Child-Turcotte-Pugh (CTP) A and CTP B disease were 47.6 mcg/mL and 66.9 mcg/mL, respectively. CONCLUSIONS: Although cetuximab could be safely administered with tolerable toxicity profiles, it demonstrated no antitumor activity in HCC in this phase 2 study. Cetuximab trough concentrations were not notably altered in patients with mild to moderate hepatic dysfunction.
30
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Frances A. Shepherd, José Rodrigues Pereira, Tudor–Eliade Ciuleanu et al. · New England Journal of Medicine · 2005 · 5.5K citations · Full text
Medicine, Oncology, Pharmacology +15
Ahmedin Jemal, Rebecca L. Siegel, Elizabeth M. Ward et al. · CA A Cancer Journal for Clinicians · 2006 · 5.3K citations · Full text
Estimating the world cancer burden: Globocan 2000
D. Maxwell Parkin, Freddie Bray, Jacques Ferlay et al. · International Journal of Cancer · 2001 · 3.7K citations · Full text